A Study of Standard of Care Drugs With or Without Ivermectin for Daraxonrasib-Induced Skin Toxicity in People With Pancreatic Cancer

Prior treatment

• Concurrent use of another investigational drug or device for the daraxonrasib-induced skin toxicity (i.e., outside of study treatment) during, or within 4 weeks of study treatment.
• Patients receiving prednisone 10 mg/day or higher (or equivalent) at the time of randomization for indications other than daraxonrasib skin toxicity management.
• Patients receiving tetracyclines, ivermectin or other systemic medication that could mask daraxonrasib rash development.

Other illness

• Documented allergy to oral ivermectin and / or minocycline
• Any condition which, in the investigator's opinion, makes the patient unsuitable for trial participation.

Other

• Pregnancy or planned pregnancy during the study period.

• Patients must have advanced pancreatic ductal adenocarcinoma with intent to daraxonrasib as standard of care monotherapy
• Female or male aged 18 years and older at the time of enrollment.
• Not pregnant and not nursing.
• No active infection requiring parenteral antibiotic(s).
• Patients have no intent to receive other anti-cancer therapy beyond daraxonrasib
• No history of allergic reaction to the study agent(s), compounds of similar chemical or biologic composition to the study agent(s) (or any of its excipients).
• Patients who are able to understand and willing to sign the written informed consent form or patients who have impaired decision-making capacity but have a legally authorized representative who can consent on their behalf are eligible. A signed informed consent form must be appropriately obtained prior to the conduct of any trial-specific procedure.